Combination therapy of ischemic heart disease using Armadin and Trizipin — another option or a unique opportunity?

S.O. Andriievska, H.O. Bezsmertna

Abstract


Background. The article presents the data of the COMETA study on the effectiveness of the combination of Armadin + Trizipin preparations, injection and tablet forms, by the domestic manufacturer Microkhim Research and Production Company, Ltd, in the comprehensive treatment of patients with ischemic heart disease (IHD) and high cardiovascular risk (HCR) in a day cardiology hospital and outpatient clinic, provides an integral evaluation of the validity of using the develo­ped treatment regimen for a month and du­ring long-term follow-up. Materials and methods. The study included 30 patients with IHD and HCR who received standard therapy according to the ESC recommendation. In addition, i.v. drip infusions of Armadin (200 mg per 100.0 saline solution), Trizipin (1000 mg i.v. in the tube at 1 : 2 dilution in saline solution), Armadin long 300 mg, 1 tablet in the evening — for two weeks, then during four weeks Trizipin long 1000 mg in the morning, Armadin long 300 mg, 1 tablet in the morning and in the evening were administered. The efficiency of the prescribed complex was monitored by the dynamics of clinical status, treadmill test (t/test), 6-minute walk test, echocardioscopy, Holter ECG monitoring (HECGM) using standard techniques; self-evaluation of the quality of life was carried out according to the classic questionnaire using the MOS 36-Item Short-Form Health Survey (SF-36). Results. We have established a positive dynamics in the clinical state of patients, the prevalence of statistically reliable indicators of objective researches: t/test — an increase in the tolerance to physical activity by 3.4 МЕТ, an increase in the distance traveled during 6-minute walk test and transition of 33.3 % of patients into the category of persons with a mild functional class of the disease, a decrease in the number of atrial and ventricular extrasystoles in HECGM and, most importantly, the elimination of short paroxysms of ventricular tachycardia. The questioning of patients with regard to the dynamics of the quality of life assessment showed a positive result in the basic criteria of the questionnaire: role functioning conditioned by the physical and emotional state improved by half (before and after — 50 and 100, 33 and 67, respectively). Conclusions. Comprehensive treatment with Armadin and Trizipin preparations (injection, tablet form) is a successful technology of therapy and rehabilitation of patients with IHD and HCR. Further long-term observations with long-term use of the technique in a permanent regimen are worthwhile. The combination of Armadin + Trizi­pin preparations by the domestic manufacturer Microkhim Research and Production Company, Ltd is promising in terms of active study as a part of the comprehensive therapy of IHD patients and introduction into a wide medical practice with the purpose of increasing therapeutic effectiveness.


Keywords


ischemic heart disease; high cardiovascular risk; day hospital; comprehensive treatment; Armadin; Trizipin

References


Gayet J.L., Paganelli F., Cohen-Solal A. Update on the medical treatment of stable angina // Archives of cardiovascular diseases. — 2011. — 104 (10). — 536-544.

Дячук В.Д. Денний стаціонар — сучасна, економічно обґрунтована форма амбулаторно-поліклінічної допомоги населенню // Довкілля та здоров’я. — 2011. — № 3. — С. 2430.

Goff D.C., Lloyd-Jones D.M., Bennett G. et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines // J. Am. Coll. Cardiol. — 2014. — 63. — 2935-2959.

Serebrovskaja T.V., Shatilo V.B. Experience of using interval hypoxia in prevention and treatment of cardiovascular di­seases: Review // Circulation and haemostasis. — 2014. — 1–2. — 16-33.

Arkhipenko Yu.V., Sazontova T.G., Tkatchouk E.N., Meerson F.Z. Adaptation to continuous and intermittent hypoxia: role of the active oxygen-dependent system. «Adaptation Biology and Medi­cine (Vol. 1. Sub-cellular Basis)» (Eds. B.K. Sharma et al.). — New Dehli: Narosa Publishing House, 1997. — 251-259.

Сиренко Ю.Н., Радченко А.Д., Михеев К.В., Рековец О.Л. Сравнительная эффективность тиотриазолина и мельдония у больных стабильной стенокардией напряжения ІІ–ІІІ функционального класса: результаты проспективного сравнительного рандомизированного исследования // Новости медицины и фармации. — 2011. — 17. — 6-9.

Liepinsh E. Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rate heart infarction / E. Liepinsh, R. Vilskersts, D. Loca // J. Cardiovasc. Pharmacol. — 2006. — 48 (6). — 314-319.

Kalvinsh I.J. Mildronate: the pharmacodynamics and perspectives of drug application. — Riga: Grindex, 2002. — 112 р.

Montalescot G., Sechtem U., Ashenbah S. et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery di­sease of the European Society of Cardiology // Eur. Heart. J. — 2013. — 34 (38). — 2949-3003.

Дзяк Г.В., Васильева Л.И., Сапожниченко Л.В. Оценка эффективности тиотриазолина по данным тредмил-теста в комплексном лечении больных со стабильными формами ишемической болезни сердца // Новости медицины и фармации. — 2011. — 14. — 6-9.

Belenkov Ju.N. Coronary artery disease as the main cause of heart failure // Heart failure. — 2004. — 5 (2). — 77-85.

Belenkov Ju.N., Mareev V.Ju., Ageev F.T., Danieljan M.O. The first results of a national epidemiological study — epidemiological examination of patients with chronic heart failu­re in actual practice (for uptake) Age-O-CHF. On behalf of the working group “Society for heart failure” // Heart failure. — 2003. — 3. — 116-120.

Kosuge M., Kimura K., Ishikawa T. et al. Combined prognostic utility of ST segment in lead aVR and troponin T on admission in nonST-segment elevation acute coronary syndromes // Am. J. Cardiol. — 2006. — 97. — 334-339.

Nough H., Jorat M.V., Varasteravan H.R et al. The va­lue of ST-segment elevation in lead aVR for predicting left main coronary artery lesion in patients suspected of acute coronary syndrome // Rom. J. Intern. Med. — 2012. — 50 (2). — 159-164.

Drapkina O.V. Quality of Life in Patients with Coronary Artery Disease // Difficult. Patient. — 2014. — 7. — 12-16.

Albert S.M., Castillo-Castenda C.D., Sano M., Jacobs D.M., Marder K., Bell K., Bylsma F., Lafleche G., Brandt J., Albert M., Stern Y. Quality of life in patients with Alzheimeris di­sease as reported by patient proxies // J. Am. Geriatr. Soc. — 1996. — 44. — 1342-1347

World Health Organisation: Adherence to long-term thera­pies, evidence for action. — Geneva: WHO, 2003. — 230 p.

From compliance to concordance: achieving shared goals in medicine taking / The Royal pharmacentical society of Great Britain. Working Party report. — 1998. Available at: www.medicinespartnership. org Accessed 05 Dec 2012.

Belsey J., Savelieva I., Mugelli A., Camm A.J. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis // Eur. J. Prev. Cardiol. — 2015. — 22 (7). — 837-848.

Голієнко Л.І. Проблеми та перспективи розвитку денних стаціонарів загального профілю на сучасному стані // Ліки України. — 2002. — № 2. — С. 1213; № 3. — С. 1315.

Денисов И.Н., Черниенко Е.И., Лавришева Т.А. и др. Проблемы дневных стационаров в общей врачебной практике // Вестник семейной медицины. — 2006. — № 1. — С. 812.

Лапач С.Н. Основные принципы применения статистических методов в клинических испытаниях / С.Н. Лапач, А.В.Чубенко, П.Н. Бабич. — К.: Морион, 2002. — 160 с.




DOI: https://doi.org/10.22141/2224-1485.4.54.2017.109543

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru